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Abstract 
 
In pediatric patients, hyperammonemia can be caused by various acquired or inherited 
disorders such as urea cycle deficiencies or organic acidemias. The brain is much more 
susceptible to the deleterious effects of ammonium during development than in adulthood. 
Hyperammonemia can provoke irreversible damages to the developing central nervous system 
that lead to cortical atrophy, ventricular enlargement and demyelination, responsible for 
cognitive impairment, seizures and cerebral palsy. Until recently, the mechanisms leading to 
these irreversible cerebral damages were poorly understood. Using experimental models 
allowing the analysis of the neurotoxic effects of ammonium on the developing brain, these 
last years have seen the emergence of new clues showing that ammonium exposure alters 
several amino acid pathways and neurotransmitter systems, as well as cerebral energy 
metabolism, nitric oxide synthesis, oxidative stress, mitochondrial permeability transition and 
signal transduction pathways. Those alterations may explain neuronal loss and impairment of 
axonal and dendritic growth observed in the different models of congenital hyperammonemia. 
Some neuroprotective strategies such as the potential use of NMDA receptor antagonists, 
nitric oxide inhibitors, creatine and acetyl-L-carnitine have been suggested to counteract these 
toxic effects. Unraveling the molecular mechanisms involved in the chain of events leading to 
neuronal dysfunction under hyperammonemia may be useful to develop new potential 
strategies for neuroprotection.   
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Abbreviations 
ASL: argininosuccinate lyase; APV: 2-amino-5-phosphonovaleric acid; ASS: 
argininosuccinate synthetase; CATs: cationic amino acid transporters; ChAT: choline 
acetyltransferase; CNS: central nervous system; CPS-1: carbamoylphosphate synthetase 1; 
CSF: cerebrospinal fluid; GS: glutamine synthetase; HHH: hyperammonemia-
hyperornithinaemia-homocitrullinuria syndrome; IQ: intellectual quotient; KO: knock-out; 
LTP: long term potentiation; MAP-2: microtubule associated protein 2; MAPK: mitogen-
activated protein kinase; MPT: mitochondrial permeability transition; MRI: magnetic 
resonance imaging ; NFM: medium weight neurofilament protein; NH4+: ammonium; 
NMDA: N-methyl-D-aspartate; NO: nitric oxide; NOS: nitric oxide synthase; ORNT1: 
ornithine citrulline antiporter 1; OTC: ornithine transcarbamoylase; y+LAT1: cationic amino 
acid y+ L-associated transporter 1 (system y+L). 
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1: Introduction 
 
Ammonia is produced by amino acid metabolism and intestinal urease-positive bacteria, and 
is mostly present as ammonium (NH4+) at physiological pH in the circulation. NH4+ is 
maintained at low concentrations (50-150 µM in preterm neonates, 50-75 µM in term 
neonates, and <50 µM in adults; Donn and Banagale, 1984) by the urea cycle (Fig. 1), which 
converts NH4+ to urea in the liver prior to excretion of urea by the kidneys (Morris, 2002). 
The complete urea cycle is expressed only in the liver. In particular, the brain is unable to 
convert NH4+ to urea due to its lack of carbamoylphosphate synthetase 1 (CPS-1) and 
ornithine transcarbamoylase (OTC), despite expressing argininosuccinate synthetase (ASS), 
argininosuccinate lyase (ASL) and arginase 1. In the central nervous system (CNS), NH4+ is 
maintained however at relatively low concentrations by the action in astrocytes of glutamine 
synthetase (GS), which converts glutamate and NH4+ to glutamine (Felipo and Butterworth, 
2002).  
 
In adults, liver failure results in hyperammonemia responsible of a potentially severe 
neuropsychiatric disorder named hepatic encephalopathy, that progressively leads to altered 
mental status and coma. The symptoms of hepatic encephalopathy in adults can be reversed 
when NH4+ concentration returns to normal levels, provided that terminal cerebral edema is 
not reached. In pediatric patients, hyperammonemia can be caused by various inherited or 
acquired disorders (Table 1) (Donn and Banagale, 1984; Leonard and Morris, 2002), the most 
frequent being urea cycle disorders with an overall prevalence estimated at 1:8200 in the 
United States (Gropman and Batshaw, 2004). The developing brain is much more susceptible 
to the deleterious effects of NH4+ than is the brain of the adult. Hyperammonemia can 
provoke irreversible damages to the developing CNS, with presentation symptoms such as 
cognitive impairment, seizures and cerebral palsy (Flint Beal and Martin, 1998). 
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Hyperammonemic neonates and infants develop cortical atrophy, ventricular enlargement, 
demyelination or gray and white matter hypodensities (Msall et al., 1984; Harding et al., 
1984; Filloux et al., 1986; Dolman et al., 1988; Wakamoto et al., 1999; Takeoka et al., 2001; 
Yamanouchi et al., 2002; Takanashi et al., 2003b; Majoie et al., 2004). The extent of  the 
irreversible damages depends on the maturation of the brain and on the magnitude and 
duration of the exposure to NH4+. Irreversibility mainly occurs in case of prolonged 
hyperammonemic crises and/or when blood NH4+ reaches levels between 200 and 500 µM, 
during the two first years of life (Msall et al., 1984; Uchino et al., 1998; Bachmann, 2002; 
Bachmann, 2003). This review will focus on the most recent advances in understanding the 
toxicity of hyperammonemia on the developing CNS. 
 
 
2: Hyperammonemia in newborns and infants 
 
2.1: Clinical presentation and treatments 
 
Most patients with urea cycle disorders commonly present in the neonatal period with non-
specific symptoms, which can be poor feeding, vomiting, somnolence, irritability and 
tachypnoea (Leonard and Morris, 2002). With the rise in plasma NH4+, symptoms can 
progress rapidly towards hypothermia, lethargy and coma (Summar, 2001). In particular, 
hyperammonemia generates edema in CNS, due to astrocyte swelling, which leads to an 
increase in intracranial pressure and to brain herniation (Cordoba and Blei, 1996; Norenberg 
et al., 2005). Neurological problems such as seizures, abnormal posture and neuromuscular 
irritability are frequent and accentuated depending on the degree of the CNS swelling and of 
the rise of pressure on brain stem (Butterworth, 1998). Brain edema leads to hyperventilation 
and respiratory alkalosis, progressing to hypoventilation and apnoea (Brusilow and Maestri, 
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1996). Untreated, most babies will die, often with complications such as cerebral or 
pulmonary haemorrhage. Survivors from these episodes will eventually exhibit mental 
retardation, the degree of retardation correlating with the level and duration of neonatal 
hyperammonemia (Msall et al., 1984; Leonard and Morris, 2002), with no normal cognitive 
outcome, or a fatal issue, occuring if plasma NH4+ exceeds 300 µM at the presentation of the 
patients or reaches a peak above 500 µM (Bachmann, 2003; Enns et al., 2007).   
 
In patients presenting with partial enzyme deficiencies of the urea cycle, the first recognized 
clinical episode may be delayed for months or years. NH4+ accumulation may be triggered by 
illness or catabolic stress resulting in multiple mild elevations of plasma NH4+ concentrations. 
The hyperammonemia is then less severe than in newborn patients and the symptoms milder 
(Takanashi et al., 2002). In most patients late-onset hyperammonemic episodes are marked by 
loss of appetite, cyclic vomiting, lethargy, and behavioral abnormalities (Smith et al., 2005; 
Harada et al., 2006). Protein avoidance may also be one of the symptoms found in patients 
with partial enzyme deficiencies, especially in female OTC deficient patients (Scaglia et al., 
2002). Many of those patients also remain mentally retarded or have learning difficulties. 
 
The immediate therapeutic goal for neonatal hyperammonemic conditions is the quick 
removal of ammonia. Proteins should be restrained from diet, in particular in case of severe 
neonatal hypermamonemia. When the metabolic alteration cannot be controlled rapidly, 
patients have to be dialyzed, preferentially through hemodialysis, hemodiafiltration or 
continuous veno-venous hemofiltration (Leonard et al., 2007). To reverse catabolism in this 
critical phase, patients are given glucose intravenously, together with spare insulin infusion to 
avoid swings in glucose levels (Summar, 2001). The metabolic control of NH4+ levels in this 
neonatal acute phase makes use of intravenous infusion of sodium benzoate and sodium 
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phenylacetate, that create alternative pathways for nitrogen excretion (Brusilow et al., 1979; 
Shih, 2007). Following these short term measures, the long term control of NH4+ uses oral 
treatments with the same compounds or sodium phenylbutyrate, in combination with a low-
protein diet (Feillet and Leonard, 1998; Berry and Steiner, 2001; Batshaw et al., 2001; Enns et 
al., 2007). Acute intercurrent crisis of hyperammonemia are treated again with intravenous 
infusion of these compounds. Moreover, nitrogen excretion is promoted by large doses of 
arginine given to ASS and ASL deficient patients, while citrulline is preferred for the 
treatment of CPS-1 and OTC deficiencies (Brusilow et al., 1979; Leonard and Morris, 2002). 
Orthotopic liver transplantation has to be considered for the more severe urea cycle defects 
such as CPS-1 and OTC deficiencies (Lee and Goss, 2001). Even with early diagnosis and 
intensive treatment, mortality is high and neurological problems are frequent in survivors 
(Bachmann, 2003). 
 
Very recently, new additional measures have been proposed, in combination with the 
conventional treatments described above, for the prospective treatment of babies at risk of 
neonatal hyperammonemia because of familial history (Leonard et al., 2007). 
 
2.2: Irreversible effects on the developing brain  
 
Mental retardation, as symptom of irreversible damage to the developing brain, is observed in 
the majority of children surviving with inborn errors of urea cycle. Important decrease in 
intellectual quotient (IQ), often combined with one or more neurological disabilities, is found 
in these patients, with strong correlations between the degree of IQ decrease, the level of 
developmental disabilities, the gravity of brain abnormalities as observed by computed 
tomography or magnetic resonance imaging (MRI), and the level, the duration and the age at 
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onset of hyperammonemia (Msall et al., 1984; Nagata et al., 1991; Bachmann, 2003). 
Neonatal onset of hyperammonemia leads to the most severe brain damages and the least IQ 
score. 
 
Brain MRI of patients with neonatal onset of hyperammonemia resulting from different urea 
cycle disorders have shown important volume loss of specific parts of the developing CNS 
(Msall et al., 1988). In particular, diffuse cortical atrophy and lesions in basal ganglia have 
been observed in OTC and CPS-1 deficient patients, sometimes with cortical multicystic 
formations and appearance of myelination delay (Yamanouchi et al., 2002; Takanashi et al., 
2003b). The same observations were also made in an ASS deficient neonate, with also lesions 
in thalamic nuclei, and a probable injury of the oligodendro-axonal unit (Majoie et al., 2004). 
MRI observation of brain lesions within the very few first days of life (0 to 8 days) in some 
patients with OTC, CPS-1 and ASS deficiencies suggests that some of these lesions or defects 
of development due to urea cycle diseases might be acquired already in utero (Harding et al., 
1984; Filloux et al., 1986; Takeoka et al., 2001; Majoie et al., 2004). In particular, it was 
proposed that the hypomyelination found in OTC neonates might be due to prenatal damages 
to oligodendrocytes, and that the multiple bilateral cerebellar heterotopia observed in the same 
patients might be the consequence of an arrest of neuronal migration in the embryonic 
cerebellum (Harding et al., 1984). Since OTC deficiency is an X-linked disorder, it is 
conceivable that fetal metabolic insufficiencies may not be fully compensated by the maternal 
organism. Filloux et al. postulated that the brain lesions described in the first days of life 
represent the initial neuropathological manifestations that, in case of prolonged survival, lead 
in part to the atrophic and degenerative changes observed later (Filloux et al., 1986). 
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Patients with later onset of hyperammonemia may have a normal neurodevelopment, if the 
diagnosis is made before they sustain an irreversible cerebral insult (Kurihara et al., 2003); 
however, many remain mentally retarded or have learning difficulties. Brain MRI of patients 
with late-onset OTC deficiency have shown injury to the cortex including acute ischemia, 
ventricular dilatation and defects of myelination (de Grauw et al., 1990; Kurihara et al., 2003; 
Takanashi et al., 2003a). Similar lesions were found in late onset CPS-1, ASS and arginase 1 
deficiencies (Call et al., 1984; Scaglia and Lee, 2006; Choi et al., 2006; Kim et al., 2006), as 
well as in patients with organic acidemias such as propionic acidemia, or with 
hyperammonemia-hyperornithinaemia-homocitrullinuria (HHH) syndrome, and presenting 
with a normal neonatal life (Harding et al., 1991; Salvi et al., 2001). 
 
The rare analyzed autopsy cases of urea cycle deficiencies reveal, depending on the age of 
death and whether they developed neonatal or late onset hyperammonemia, microcephaly, 
shrinkage of hemispheres with appearance of multiple cysts, ventricular dilatation, atrophy or 
necrosis of various nuclei (particularly in caudate putamen, thalamus and hypothalamus) and 
defects of myelination (Dolman et al., 1988; Takeoka et al., 2001; Yamanouchi et al., 2002). 
Microscopically, the brain tissue often appears spongy with extensive neuronal loss 
(particularly in cortex and hippocampus), is markedly gliosed and presents astrocytes with 
water-clear, oval nuclei characteristic of Alzheimer’s type II astrocytes. Recently, 
emperipolesis, i.e. the active penetration of one cell by another one which remains intact, has 
also been described in the cerebral white matter of a 46-years old patient with ASS 
deficiency, where oligodendrocytes have been shown engulfed within hypertrophic astrocytes 
(Nishie et al., 2006). 
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In contrast with the developing brain, hyperammonemia (generally associated with liver 
failure) does not result in significant neuronal loss or structural damage to neurons in the adult 
brain (Butterworth, 2003). 
 
 
3: Experimental models for the study of the effects of hyperammonemia on 
the developing CNS 
 
3.1: The sparse-fur mouse 
 
The sparse-fur (spf) mouse is an ideal animal model to study the effects of hereditary 
hyperammonemia, as this mouse has a single point substitution in the OTC gene, with an X 
linked transmission (Qureshi 1979, Veres 1987). Two mouse strains with OTC mutations 
have been described: sparse-fur (spf) and sparse-fur with abnormal skin and hair (spf ash) 
(Doolittle et al., 1974; DeMars et al., 1976). The hepatic OTC activity is 5 to 10% in the spf 
ash and 13% in the spf, as compared to the normal mice (Qureshi and Rao, 1997). Adult spf/Y 
mice (12 weeks old) show plasma and brain NH4+ levels increased 1.5 and 5 fold respectively 
(Ratnakumari et al., 1992). In these mice, a 3-fold increase in blood NH4+ is observed 
immediately after weaning as compared to control litter mates, which is probably due to 
dietary change from mother’s milk to the conventional laboratory chow and to the subsequent 
changes in the intestinal flora from non-urease producing to urease producing bacteria that 
increase blood NH4+ level (Gushiken et al., 1985; Inoue et al., 1987). Recent analysis of the 
spfash mice have shown that despite their reduced OTC activity, these mice are able to 
detoxify ammonia and keep normal ureagenesis when they are infused with a balanced, 
complete mixture of amino acids, while an unbalanced amino acid infusion (i.e. a glycine-
alanine mixture) make them hyperammonemic and decreases their ureagenesis (Marini et al., 
2006b). This ability of spf mice to detoxify ammonia and keep normal ureagenesis under 
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balanced amino acids is probably due to the presence of arginine in the complete mixture of 
amino acids. Neuropathologic studies in the spf mouse revealed similar brain alterations as 
those observed in patients with OTC deficiency. Spf mice exhibit an overall brain size 
reduction with a reduced volume of the striatum and ventricular enlargement (Hopkins et al., 
1998).  
 
3.2: Knock-out mice 
 
Knock-out (KO) mice as models of other urea cycle deficiencies have been developed 
recently: ASL, arginase 1 and arginase 2 deficient mice, as well as double KO mice for 
arginases 1 and 2 (Iyer et al., 2002; Reid Sutton et al., 2003; Deignan et al., 2006). 
Homozygous ASL-/- null mice die within 48h after birth with plasma NH4+ increased 4 fold. 
Arginase 1 KO mice and arginases 1/2 double KO mice die from hyperammonemia at 14 days 
postnatally, with a 10-fold increase in plasma NH4+ level, while arginase 2 KO mice have no 
obvious phenotype (Iyer et al., 2002; Reid Sutton et al., 2003; Deignan et al., 2006). 
Neuropathological studies have not yet been published for these KO mice. Anyhow, as these 
enzymes are normally expressed in brain cells, ASL, arginase 1 and arginase 2 deficiencies 
may alter normal brain development independently of hyperammonemia (Braissant et al., 
1999a; Yu et al., 2001), hampering thus the study of the specific effects of NH4+ toxicity on 
the developing CNS in these models. 
 
3.3: Rats models of congenital hyperammonemia 
 
In vivo, long-term effects of chronic hyperammonemia have also been studied in rat models 
of congenital hyperammonemia. Authors exposed rats to NH4+ during prenatal and lactation 
periods by feeding the pregnant rats with an NH4+ acetate-containing diet from day 1 of 
pregnancy until weaning (at postnatal day 21). After weaning, pups were also fed the NH4+ 
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containing diet (Aguilar et al., 2000; Munoz et al., 2000). The amount of NH4+ in the brain of 
these hyperammonemic rats increased 1.4 times compared to control rats (Munoz et al., 
2000).  
 
3.4: Reaggregating brain cell 3D cultures treated with NH4Cl 
 
Our research team has developed reaggregating brain cell 3D cultures as a valid experimental 
model to study the specific effects of NH4+ toxicity on the developing CNS (Braissant et al., 
1999b; Honegger and Monnet-Tschudi, 2001; Braissant et al., 2002; Braissant et al., 2006). 
These are primary cell cultures prepared from the CNS of rat embryos, containing all types of 
brain cells (neurons, astrocytes, oligodendrocytes and microglia) and consisting of even-sized, 
spherical structures that are maintained in suspension by constant gyratory agitation in a 
serum-free, chemically defined medium. Cells are able to migrate within the formed 
reaggregated structures, and to interact with each other by direct cell-cell contacts, as well as 
through exchange of nutritional and signaling factors. This tissue-specific environment 
enables aggregating neural cells to differentiate, and to develop specialized structures 
(synapses, myelinated axons) resembling those of the brain tissue (Honegger and Monnet-
Tschudi, 2001). Aggregating cell cultures are therefore classified as organotypic cultures 
(Doyle et al., 1994). Chronic hyperammonemia is mimicked in this model by treating the 
cultures with 5 mM NH4Cl for 8 days (Braissant et al., 1999b; Braissant et al., 2002). We 
have thus shown that axonal growth, as well as medium weight neurofilament (NFM) 
expression and phosphorylation, are altered by NH4Cl exposure (Braissant et al., 2002). This 
occurs only in developing brain cell aggregates (treated from days 5 to 13: a period at which 
neurons progressively develop their processes) but not in more mature cultures (treated from 
day 20 to 28: a period at which neurons progressively undergo synaptogenesis and 
myelination) (Honegger and Monnet-Tschudi, 2001; Braissant et al., 2002). This difference in 
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vulnerability of the brain depending on its maturation level is in line with clinical data 
showing that hyperammonemia causes irreversible CNS damages such as neuronal cell loss in 
neonates and infants but not in adults (Brusilow and Horwich, 2001). Compared to classical 
brain cell cultures, brain cell reaggregated cultures present the advantage to allow the study of 
irreversible NH4+ toxicity in a model that mimic brain complexity at different stages of 
maturation. In the same time, these cultures allow to study the effects of hyperammonemia 
devoid of confusing variables attributable to secondary effects of hyperammonemia found in 
animal models (Bachmann, 1992).  
 
3.5: Other models of hyperammonemia 
 
Hyperammonemia has been experimentally induced in vivo on adult rats by several other 
methods, including the intraperitoneal injection with NH4+-acetate or infusion with urease 
(Robinson et al., 1992b), NH4+-acetate containing diet (20% weight) (Azorin et al., 1989) or 
portacaval anastomosis (Song et al., 2002). In vitro, toxic effects of NH4+ have been studied 
on primary cultures of neurons or astrocytes (Chan et al., 2000; Schliess et al., 2002; 
Jayakumar et al., 2006) and on hippocampal rat brain slices (Chepkova et al., 2006). These 
models have provided several clues for the mechanisms of NH4+ toxicity on brain cells, but 
they do not allow the analysis of the effects of hyperammonemia on the developing CNS,  in 
particular in its cellular complexity and the relationships between developing neurons and 
glial cells. 
 
 
4: Toxicity of ammonium on experimental models of the developing CNS  
 
4.1: Amino acids disturbances 
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4.1.1: Glutamine 
As glutamine synthesis is the major brain pathway for the removal of NH4+, 
hyperammonemic conditions with high levels of NH4+ in CNS should increase the synthesis 
of brain glutamine. As a result, a 2 to 3 fold increase in brain glutamine was reported by 
proton spectroscopy in two females with OTC deficiency (Connelly et al., 1993). A 2-fold 
increase in glutamine level was also reported in the brain of spf mice (Inoue et al., 1987). 
These results are confirmed by in vitro studies showing that NH4Cl exposure of aggregating 
brain cell cultures increases their intracellular concentration of glutamine (Bachmann et al., 
2004). 
 
4.1.2: Glutamate 
Glutamate concentrations are significantly reduced in cerebral cortex (but not in other brain 
regions) of spf mice as well as in NH4Cl-exposed brain cell 3D cultures prepared from 
embryonic rat telencephalons (Ratnakumari et al., 1994a; Bachmann et al., 2004). This could 
be the result of increased glutamine formation from NH4+ and glutamate or of a loss of 
glutamatergic neurons (Qureshi and Rao, 1997). 
 
4.1.3: Arginine 
Arginine is an essential amino acid for the foetus and the neonate, who however synthesize 
parts of their arginine needs through the combined expression of CPS-1, OTC, ASS and ASL 
in the intestine (Husson et al., 2003; Curis et al., 2005). In the adult, arginine is considered a 
conditionally essential amino acid, and its endogenous synthesis pathway is decoupled 
between CPS-1 and OTC expressed in the intestine (while ASS and ASL are repressed) and 
synthesizing citrulline, and ASS and ASL being induced in proximal tubule cells of the 
kidney, which synthesizes arginine from the incoming citrulline produced by intestine (Wu 
and Morris, 1998; Husson et al., 2003). As a consequence, patients with urea cycle disorders 
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(except those with arginase 1 deficiency) have decreased plasma arginine concentrations and 
need a supplement of arginine to replace that which is not synthesized (Leonard and Morris, 
2002; Scaglia et al., 2004; Scaglia and Lee, 2006). Severely affected CPS-1 and OTC 
deficient patients are better treated with citrulline rather than arginine  (Leonard and Morris, 
2002). As arginine is precursor for nitric oxide (NO) and creatine synthesis, urea cycle 
deficiencies can lead to disturbances of the citrulline-NO cycle (Fig. 2) (see 4.4: alteration of 
NO synthesis) and an alteration of creatine metabolism (Fig. 3) (see 4.3: cerebral energy 
deficit), including in brain cells (Braissant, 2007). Spf mice, which are deficient in their own 
arginine synthesis as are OTC-deficient patients, present decreased levels of arginine in their 
brain (Ratnakumari et al., 1996b). In contrast, experimental models with no evidence of 
arginine depletion show increased levels of arginine in brain cells placed under NH4+ 
exposure, as it was shown in aggregating brain cell 3D cultures exposed to NH4Cl (Bachmann 
et al., 2004) and in rat cerebellar synaptosomes exposed to NH4+-acetate (Rao, 2002). This 
might be due to the NH4+-induced expression of ASS and ASL in astrocytes (Braissant et al., 
1999b). 
 
4.1.4: Other amino acids 
Plasma ornithine and citrulline levels are low in spf mice (Qureshi and Rao, 1997). 
Interestingly, ornithine supplementation to hyperammonemic spf ash mice can decrease their 
hyperammonemia and restore their ureagenesis, suggesting that ornithine has the potential to 
correct OTC deficiency in spf ash mice (Marini et al., 2006a). Finally, large neutral amino 
acids (tyrosine, phenylalanine, methionine, tryptophan and histidine) accumulates in the brain 
of spf mice (Bachmann and Colombo, 1984; Inoue et al., 1987). 
 
4.2: Alterations in the neurotransmitter systems 
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4.2.1: Glutamatergic system 
An hypothesis to explain the neuronal loss observed under hyperammonemia involves 
excitotoxicity injury through N-methyl-D-aspartate (NMDA) receptors. Although NH4+ is 
presumed to be the principal neurotoxin, there is evidence that other neurochemical alterations 
may also be involved. Tryptophan, which is increased under hyperammonemia (Bachmann 
and Colombo, 1984), can be oxidized to quinolinic acid, an excitotoxin acting on NMDA 
receptors. As a result of tryptophan increase, quinolinic acid is increased in the cerebrospinal 
fluid (CSF) of children with congenital hyperammonemia as well as in various regions of spf 
mice brain (Batshaw et al., 1993; Robinson et al., 1995). Infusion of quinolinic acid into the 
brain is associated with selective death of spiny neurons in the striatum (Schwarcz and 
Kohler, 1983; Robinson et al., 1995). This result is consistent with the loss of spiny neurons 
observed in the striatum in spf/Y mice (Robinson et al., 1995; Ratnakumari et al., 1995b) and 
suggests that NH4+ neurotoxicity may be mediated by quinolinic acid in patients with 
congenital hyperammonemia (Fig. 2). 
 
The release of endogenous glutamate, induced by depolarization, from synaptosomes isolated 
from spf mice at 35 days is significantly elevated, while the uptake of glutamate into 
synaptosomes is significantly reduced (Rao and Qureshi, 1999).  These results suggest that the 
level of extracellular glutamate is increased in the brain of spf mice. This is in accordance 
with the increased level of extracellular glutamate observed by microdialysis in rabbit with 
acute hyperammonemia as well as with experiments showing that NH4+ leads to glutamate 
release from cultured astrocytes (de Knegt et al., 1994; Rose et al., 2005). Moreover, the 
astrocytic glutamate transporter GLAST is decreased under NH4+ exposure, leading to a 
decreased re-uptake of extracellular glutamate (Fig. 2) (Chan et al., 2000). As a consequence 
of a persistent release of excess glutamate, a significant reduction in NMDA receptors has 
been shown in the cerebral cortex of spf mice (Hopkins and Oster-Granite, 1998; Rao and 
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Qureshi, 1999). This down-regulation might be a mechanism of protection against excess 
stimulation of the NMDA receptors by glutamate and/or quinolinic acid, which induces 
excitotoxicity by the activation of an intracellular cascade responsible for neuronal 
dysfunctions and death (Ratnakumari et al., 1995a). Although NMDA receptors may be 
down-regulated, a certain level of persistent excitotoxicity may continue and lead to the 
neuronal loss observed in patients with congenital hyperammonemia (Rao and Qureshi, 
1999). Interestingly, NMDA receptor antagonists MK-801 and 2-amino-5-phosphonovaleric 
acid (APV) improve neuronal survival in primary cortical neurons from newborn rats treated 
with NH4Cl (Fig. 2) (Klejman et al., 2005). Moreover, APV diminishes the impairment of 
long term potentiation (LTP) by NH4+ exposure in rat hippocampal slices (Izumi et al., 2005). 
 
4.2.2: Cholinergic system 
A significant loss of forebrain cholinergic neurons was observed in spf mice (Ratnakumari et 
al., 1994b). Similarly in aggregating brain cell 3D cultures, data showed that early in 
development cholinergic neurons were impaired by NH4Cl treatment (Braissant et al., 2002). 
A developmental study in spf mice showed that choline acetyltransferase (ChAT) activity 
level starts to decrease immediately after weaning and reaches significantly lower level in 
adult mice (Ratnakumari et al., 1995b). Moreover, subsequent studies of muscarinic 
cholinergic M1 (postsynaptic) and M2 (presynaptic) receptors revealed an up to 54% increase 
of the M1 receptor and a concomitant decrease by up to 60% of the M2 receptor in spf mice 
(Ratnakumari et al., 1996a). Increase in the M1 post-synaptic receptors could be due to an up-
regulation in response to the loss of cholinergic presynaptic neurons (Michalak and 
Butterworth, 1997). Together, these results points towards a severe impairment of cholinergic 
system by hyperammonemia.  As cholinergic system plays a crucial role in memory and other 
cognitive functions, this impairment under hyperammonemia may be responsible for 
  19 
cognitive dysfunctions observed in patients with urea cycles disorders and in spf mice 
(Russell, 1996). 
 
4.2.3: Serotoninergic system 
Tryptophan (precursor for serotonin) and 5-hydroxyindoleacetic acid (metabolite of serotonin) 
are enhanced in spf mice brain and in CSF of children with congenital hyperammonemia 
(Bachmann and Colombo, 1984; Hyman et al., 1987). Moreover, receptor binding studies in 
spf mice reveal a significant loss of 5HT2 receptor and a concomitant increase in 5HT1A 
receptor (Robinson et al., 1992a). These data demonstrate alterations of the serotoninergic 
system in congenital hyperammonemia that may be involved in anorexia and sleep 
disturbance observed in children with urea cycle disorders (Hyman et al., 1986). 
 
4.3: Cerebral energy deficit 
 
In the brain of spf mice, the ATP concentration is decreased (Ratnakumari et al., 1992), while 
a significant decrease in cytochrome C oxidase expression and activity is observed, 
suggesting that reduction in ATP levels could be due to a reduction of the activity of the 
electron transport chain enzymes (Fig. 2) (Rao et al., 1997). It has also been suggested that the 
deficit in brain energy metabolites in hyperammonemia may be due to inhibition of the TCA 
cycle, especially at the level of α-ketoglutarate dehydrogenase (Fig. 2) (Lai and Cooper, 
1986). However, it has been shown that ATP depletion alone is not enough to induce neuronal 
death (Marcaida et al., 1995).  
 
The creatine / phosphocreatine / creatine kinase system is essential for the buffering and 
transport of high-energy phosphates (Wyss and Kaddurah-Daouk, 2000), and the mammalian 
brain is able of its own creatine synthesis both in adulthood and during development 
(Braissant et al., 2001b; Braissant et al., 2005; Braissant et al., 2007). Creatine is decreased in 
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the brain of spf mice (Ratnakumari et al., 1996b). In brain cell 3D primary cultures exposed to 
NH4Cl, we have shown that axonal growth is impaired and that creatine and phosphocreatine 
are decreased (Fig. 3) (Braissant et al., 2002; Braissant et al., 2006). These studies support the 
hypothesis of an energy deficit induced by NH4+ exposure. Recent data demonstrate that NH4+ 
exposure generates a secondary creatine deficiency in brain cells, through disturbances of 
creatine transport and synthesis pathway (Braissant, Cagnon, Monnet-Tschudi, Speer, 
Wallimann, Honegger and Henry, submitted for publication). Interestingly, axonal growth is 
protected under NH4+ exposure by creatine co-treatment, in a glial cell-dependent manner 
(Braissant et al., 2002) (see also below 4.7: impairment of axonal and dendritic growth). The 
protective potential of creatine has been illustrated in numerous models of neurodegeneration 
(Fig. 2 and 3) (Brewer and Wallimann, 2000; Wilken et al., 2000). 
 
Another agent, acetyl-L-carnitine, has also been proposed for the recovery of cerebral energy 
deficits induced by NH4+. The main role of carnitine is to shuttle acyl-CoA derived from fatty 
acids across the inner mitochondrial membrane. Once inside the mitochondria, the acyl-CoA 
molecule undergoes beta-oxidation producing acetyl-CoA that can enter the Krebs cycle 
leading to the production of ATP. It has been shown that acetyl-L-carnitine is able to enhance 
the restoration of ATP and phosphocreatine levels in a model of ischemia (Aureli et al., 
1994). A treatment of pregnant spf mice with acetyl-L-carnitine, starting from day 1 of 
conception, resulted in a significant restoration of ChAT activity levels in some brain regions 
of the spf/Y offspring, suggesting that acetyl-L-carnitine may be neuroprotective in NH4+-
induced toxicity (Ratnakumari et al., 1995b). It was suggested that this protective effect may 
be due to the restoration of the cytochrome C oxidase activity in spf mice (Rao et al., 1997). 
Aside from being an essential component of fatty acid metabolism, acetyl-L-carnitine is also a 
free-radical scavenger and may contribute to the protection of cells against oxidative stress 
(Zanelli et al., 2005). 
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4.4: Alteration of nitric oxide synthesis 
 
NO is synthesized by nitric oxide synthase (NOS) from the unique precursor L-arginine. 
NOS, when expressed in concert with ASS and ASL, constitutes the citrulline-NO cycle, 
which allows the recycling of the by-product of NO synthesis, citrulline, to arginine (Fig. 2) 
(Morris, 2004). ASS and ASL can be found in almost every cell, including in the CNS, albeit 
most of the time at lower levels than when expressed for the urea cycle in hepatocytes 
(Wakabayashi, 1998; Braissant et al., 1999b; Husson et al., 2003). It has been suggested that 
to assure their specific needs in NO synthesis, brain cells depend on (i) arginine supply from 
periphery and between brain cells with the implication of the various cationic amino acid 
transporters (CATs) and other cationic amino acid carriers such as y+L-associated transporters 
(y+LATs), (ii) the regulation of arginine levels by arginase 2, and (iii) the recycling of 
citrulline to arginine by ASS and ASL, sometimes in cells different from the ones 
synthesizing NO (Braissant et al., 1999a; Wiesinger, 2001; Braissant et al., 2001a; Braissant, 
2007).  
 
In postsynaptic neurons, NO is formed following activation of glutamate receptors, mainly of 
the NMDA subtype. After this activation, Ca2+ is transiently increased in the cytosol and 
forms a complex with calmodulin that binds to and activates constitutive neuronal NOS 
(nNOS or NOS1). This leads to an increased production of NO, which in turn activates 
soluble guanylate cyclase resulting in increased concentration of cGMP. This glutamate-NO-
cGMP pathway modulates important cerebral processes such as intercellular communication 
and LTP (Rodrigo and Felipo, 2006). As NMDA receptors are activated by NH4+ exposure, it 
suggests that hyperammonemia can activate nNOS and stimulate NO synthesis in neurons 
(Fig. 2). It has been shown that treatment of primary cultures of cortical neurons with NH4+ 
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results in an increase of the cGMP level in response to SNAP, a NO-generating agent 
(Rodrigo et al., 2005). In contrast, in primary cultures of cerebellar neurons exposed to NH4+, 
the formation of cGMP is reduced following SNAP addition (Rodrigo et al., 2005). The 
mechanism by which NH4+ can lead to opposite effects in cerebellum and cerebral cortex is 
not understood by now.  
 
In glial cells, NO is synthesized after the transcriptional induction of a Ca2+-independent 
inducible NOS isoform (iNOS or NOS2). In contrast to nNOS-derived NO formation which 
occurs transiently, iNOS activity can generate high concentrations of NO (for review see 
Moncada and Bolanos, 2006). In primary cultures of astrocytes, NH4+ induces iNOS 
expression and enhances NO synthesis (Schliess et al., 2002). It is known that elevated NO 
concentrations can interact with superoxide anion, leading to the formation of the highly toxic 
peroxynitrites. Thus, the excessive formation of NO by astrocytes induced by NH4+ may 
induce peroxynitrites in the neighboring neurons, leading to neuronal death (Fig. 2). 
Moreover, it has been suggested that NH4+-induced production of NO could inhibit GS, the 
only NH4+ detoxification pathway in the brain, which might thus even worsen the 
consequences of hyperammonemia on CNS (Fig. 2) (Rose and Felipo, 2005). This increase in 
NOS activity and NO synthesis under NH4+ exposure is coherent with our observation in 
brain cell 3D cultures exposed to NH4Cl, which increase their arginine content and induce the 
astrocytic expression of ASS and ASL, thus stimulating the citrulline-NO cycle (Braissant et 
al., 1999b; Bachmann et al., 2004). 
 
NO synthesis has also been studied in vivo. The NOS activity and NO synthesis have been 
shown decreased in the brain of spf mice (Ratnakumari et al., 1996b). Similarly, in patients 
with OTC deficiency, plasmatic and urinary NO metabolites (as markers for NO synthesis) 
were shown below the normal range showing a decrease of NO synthesis (Nagasaka et al., 
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2004). This is in accordance with the decrease in arginine (precursor for NO) content 
observed under urea cycle deficiencies. In contrast, experimental models with adequate 
arginine supplementation show opposite effects on NO synthesis under hyperammonemia. For 
instance, nNOS expression is increased, both at mRNA and protein levels, in the 
hyperammonemic brain of portacaval shunted rats (Rao, 2002), and NO production is 
increased in the brain of rats exposed to NH4+-acetate (Kosenko et al., 1998).  
 
4.5: Oxidative stress 
 
Oxidative stress results from an imbalance between formation of free radicals and their 
neutralization by antioxidants. Free radicals are highly reactive, unstable molecules that have 
an unpaired electron in their outer shell. Free radicals are generally reactive oxygen or 
nitrogen species such as hydrogen peroxide, hydroxyl radical, nitric oxide, peroxynitrite and 
superoxide anion. They react with various cellular components leading to DNA damage, 
mitochondrial malfunction, cell membrane damage and eventually cell death.  
 
Increased superoxide production and decreased activities of antioxidant enzymes such as 
glutathione peroxidase, superoxide dismutase and catalase, were observed in brain rats 
injected with NH4+-acetate (Kosenko et al., 1997; Kosenko et al., 1998). In this model, 
inhibition of NOS by nitroarginine, or the use of NMDA receptor antagonists, prevent those 
changes suggesting that NH4+-induced oxidative stress is due to the increased formation of 
NO as a consequence of excessive activation of NMDA receptors (Fig. 2) (Kosenko et al., 
1998; Kosenko et al., 1999). Similarly, the production of free radicals is enhanced in a dose-
dependent manner in primary cultures of astrocytes exposed to NH4+ (Murthy et al., 2001; 
Reinehr et al., 2007).  
 
4.6: Induction of mitochondrial permeability transition  
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The mitochondrial permeability transition (MPT) is a sudden increase of the inner 
mitochondrial membrane permeability to ions and solutes, which causes disruption of 
mitochondrial inner membrane potential (maintained by the pumping out of protons by the 
electron transport chain) and diffusion of solutes down their concentration gradient. This leads 
to defective oxidative phosphorylation, cessation of ATP synthesis and the generation of 
reactive oxygen species. MPT is one of the major causes of cell death in a variety of 
conditions (Kroemer et al., 2007).  
 
In primary cultures of astrocytes, NH4+ induces a collapse of the mitochondrial inner 
membrane potential that is associated with enhanced mitochondrial permeability (Fig. 2) (Bai 
et al., 2001). Similar treatments of cultured neurons failed to produce a dissipation of the 
mitochondrial inner membrane potential, suggesting that NH4+-induced neuronal death may 
not be mediated by MPT (Bai et al., 2001). It has been shown that creatine is able to inhibit 
MPT pore opening (O'Gorman et al., 1997; Dolder et al., 2003). As MPT is causally related to 
cell death and is induced by NH4+ treatment in glial cells, creatine may represent a potential 
strategy for  the CNS protection against NH4+ toxicity (Fig. 2 and 3). 
 
4.7: Impairment of axonal and dendritic growth 
 
Cortical atrophy, ventricular enlargement, or gray and white matter hypodensities are found in 
the developing brain of hyperammonemic neonates and infants (Msall et al., 1984; Harding et 
al., 1984; Call et al., 1984; Filloux et al., 1986; Dolman et al., 1988; Uchino et al., 1998; 
Wakamoto et al., 1999; Majoie et al., 2004). These clinical findings are reminiscent of 
neuronal fiber loss or defects of neurite outgrowth (Fig. 3). A significant loss of medium 
spiny neurons and increased numbers of reactive oligodendroglia and microglia in the 
striatum are also observed (Robinson et al., 1995). Moreover in spf mice, analysis of the 
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dendritic tree of layer V pyramidal cells in frontoparietal cortex revealed a significant 
decrease in both the complexity of the dendritic arbor and in dendritic terminal spine density 
(Hopkins et al., 1998). The alteration of dendritic arbor development under hyperammonemia 
might be triggered by dysregulations of dendritic cytoskeletal elements. Felipo et al. showed 
for instance that hyperammonemic rats present a decreased phosphorylation of the dendritic 
protein microtubule associated protein 2 (MAP-2), in parallel with an increase of MAP-2 
binding to microtubules (Felipo et al., 1993). Using aggregating brain cell 3D primary 
cultures prepared from fetal rat telencephalon, we have shown that NH4+ exposure inhibits 
axonal growth, together with a decreased of NFM expression and phosphorylation (Braissant 
et al., 2002; Braissant, 2006). We further showed that the inhibition of axonal growth is 
accompanied by a decrease of creatine in the developing brain cells, and that creatine co-
treatment under NH4+ exposure can protect axonal growth and restore NFM expression and 
phosphorylation in a glial cell-dependent manner  (Fig. 3) (Braissant et al., 2002). 
 
4.8: Disturbances in signaling transduction pathways 
 
Recent works suggest that disturbances in upstream cell-signaling pathways may be 
responsible for numerous downstream mechanisms of developmental defaults or cell death in 
the brain (Mielke and Herdegen, 2000; Stanciu et al., 2000). Among these, mitogen-activated 
protein kinases (MAPKs) are good candidates for mediating upstream signals that lead to 
hyperammonemia-induced brain cell injury. MAPKs are part of an evolutionarily conserved 
mechanism that transduces extracellular signals, stress and injury to intracellular responses 
that balance survival, differentiation and death of the cell (Xia et al., 1995). Recent studies 
have shown that Erk1/2, JNK1/2/3 and p38MAPK are activated in astrocytes by NH4+ (Schliess 
et al., 2002; Jayakumar et al., 2006). Early phosphorylation of Erk1/2 and p38MAPK seems 
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responsible for NH4+-induced astrocyte swelling whereas early phosphorylation of JNK1/2/3 
and p38MAPK is involved in NH4+-induced inhibition of glutamate uptake in astrocytes 
(Schliess et al., 2002; Jayakumar et al., 2006). During CNS development, MAPKs are also 
involved in neuronal maturation and differentiation. In particular, Erk1/2 is involved in axonal 
and dendritic outgrowth, by regulating the phosphorylation state of cytoskeletal proteins such 
as neurofilaments (axons) and MAP-2 (dendrites), either directly or through activation of 
Cdk5 (Fig. 3) (Veeranna et al., 1998; Harada et al., 2001). MAPKs are dysregulated in 
NMDA excitotoxicity and cerebral ischemia (Borsello et al., 2003a; Borsello et al., 2003b), 
and have been proposed as targets in therapeutic approaches to counteract these CNS 
pathophysiological conditions (Mehta et al., 2007). Although activation levels of MAPKs 
have not been studied yet in neurons under NH4+-exposure, the manipulation of MAPK 
pathways may represent a novel therapeutic target for protecting the CNS development of 
pediatric patients with hyperammonemia from the deleterious effects of NH4+. 
 
4.9: Impairment of cognitive performance  
 
In line with clinical data showing that patients with urea cycle deficits often show mental 
retardation, several studies demonstrate that hyperammonemia induces impairment of 
cognitive performance in animal models. Using two learning tasks (passive avoidance test and 
Morris-type water maze), D’Hooge et al. have demonstrated deficits in cognitive functions in 
spf mice during episodes of hyperammonemia (D'Hooge et al., 2000). Aguilar et al. compared 
the cognitive performance of rats prenatally and neonatally exposed to NH4+, with adult rats 
exposed for 15 days (Aguilar et al., 2000). With respect to passive avoidance behavior, adult 
hyperammonemia had no effect whereas the pre/neonatal hyperammonemia produced a clear 
increase in the step-through latency, suggesting that NH4+ exposure during prenatal and 
neonatal period impairs memory or conditioned learning of the animals. Moreover, LTP, a 
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phenomenon that is considered to be the molecular basis for some forms of memory and 
learning, is markedly reduced in hippocampal slices from rats prenatally and neonatally 
exposed to ammonia (Munoz et al., 2000). The impairment of LTP in hyperammonemia could 
be responsible for at least some of the cognitive alterations found in hyperammonemic rats 
and spf mice and could be involved in the origin of the mental retardation in infants and 
children with congenital hyperammonemia. 
 
 
5: Conclusion and perspectives for neuroprotection against ammonium 
toxicity on the developing CNS 
 
In conclusion, hyperammonemia is associated with neuronal cell loss and cerebral atrophy 
that lead to mental retardation and cerebral palsy in pediatric patients. These toxic effects of 
NH4+ are specific to the developing brain, as neuronal damages are not observed in the brain 
of adult patients with hyperammonemia due to liver failure. While, for a long time, the 
mechanisms of toxic effects of NH4+ on the developing brain were poorly understood, several 
recent clues have been provided by different models of hyperammonemia such as spf mice, 
rats treated prenatally and neonatally with NH4+-acetate, as well as with brain cell 3D primary 
cultures treated with NH4Cl during the development phase. Alterations in amino acids 
synthesis, in neurotransmitter functions, in nitric oxide metabolism as well as in cerebral 
energy, induction of oxidative stress and MPT have been observed, and may be responsible 
for neuronal cell death and axonal growth inhibition. Recent studies suggest also disturbances 
in signaling transduction pathways. Some neuroprotective strategies have been suggested by 
experiments in the different models, including the use of NMDA receptor antagonists, NOS 
inhibitors, creatine and acetyl-L-carnitine (Fig. 2 and 3). 
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As illustrated in this review, unraveling new therapeutic targets to protect the brain of 
hyperammonemic neonates and infants will require experimental approaches focusing on the 
developing CNS in its cellular complexity, with neurons and glial cells interacting together. 
Thus, future studies may focus not only on the intracellular (e.g. MAPKs or others), but also 
on the extracellular signaling pathways disturbed between developing brain cells under NH4+ 
exposure.  
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Tables 
 
 
Table 1 : Causes of hyperammonemia in neonates and infants. 
 
 
Inherited disorders : 
 
Urea cycle enzymes defects  
     Carbamoylphosphate synthetase 1 (CPS-1) deficiency 
     Ornithine transcarbamoylase (OTC) deficiency 
     Arginosuccinate synthetase (ASS) deficiency (citrullinemia) 
     Arginosuccinate lyase (ASL) deficiency (arginosuccinic aciduria) 
     Arginase 1 deficiency  
     N-acetylglutamate synthetase deficiency 
 
Defects in transporters of urea cycle intermediates 
     Lysinuric protein intolerance (y+-LAT1 deficiency) 
     Hyperammonemia-hyperornithinaemia-homocitrullinuria syndrome (ORNT1 deficiency) 
     Citrin (mitochondrial aspartate glutamate carrier) deficiency 
 
Organic acidemias 
     Propionic acidemia  
     Methylmalonic acidemia  
     Β-kethiolase deficiency 
     Isovaleric acidemia 
 
Fatty acid oxidation disorders 
     Medium chain acyl-CoA dehydrogenase deficiency 
     Systemic carnitine deficiency 
     Long chain fatty acid oxidation defects 
 
Other inborn errors of metabolism 
     Pyruvate carboxylase deficiency 
     Ornithine aminotransferase deficiency 
     Δ1-pyrroline-5-carboxylate synthase (P5CS) deficiency 
 
 
Acquired disorders : 
      
     Transient hyperammonemia of the newborn 
     Herpes simplex systemic infection 
     Liver failure  
     Infection with urease positive bacteria 
     Portacaval shunt 
     Perinatal asphyxia 
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Figure legends 
 
Figure 1: Expression of the whole urea cycle in hepatocytes. Hyperammonemia occurs in 
case of deficiency in one of the six enzymes of the urea cycle (CPS-1 OTC, ASL, ASS, A-1 
and NAGS; illustrated in red), or in ORNT1, citrin or pyruvate carboxylase. Other inborn 
errors of metabolism or acquired disorders generating hyperammonemia are listed in Table 1. 
A-1: arginase 1; AAT: aspartate aminotransferase; ASL: argininosuccinate lyase; ASS: 
argininosuccinate synthetase; CPS-1: carbamoylphosphate synthetase 1; NAG: N-
acetylglutamate; NAGS: N-acetylglutamate synthetase; ORNT1: ornithine citrulline antiporter 
1; OTC: ornithine transcarbamoylase; PC: pyruvate carboxylase. 
 
Figure 2: Neurotoxicity of hyperammonemia. The toxic effects of NH4+ exposure to 
neurons and astrocytes are illustrated in red. In particular, NH4+ exposure generates oxidative 
stress, energy deficit and cell death in the central nervous system through disturbances of the 
nitric oxide pathways, inhibition of the TCA cycle, and opening of the mitochondrial 
permeability transition. The protective effects of creatine, acetyl-L-carnitine, NMDA 
antagonists and NOS inhibitors against NH4+ toxicity to brain cells are illustrated in green. 
ASA: argininosuccinate; ASL: argininosuccinate lyase; ASS: argininosuccinate synthetase; 
GLAST: NA+-dependent glutamate / aspartate transporter; GS: glutamine synthase; iNOS: 
inductible nitric oxide synthase or NOS2; MPT: mitochondrial permeability transition; 
NMDA: N-methyl-D-aspartate; nNOS: neuronal nitric oxide synthase or NOS1; NO: nitric 
oxide;  
 
Figure 3: Impairment of axonal growth by NH4+ exposure. Irreversible effects of NH4+ 
exposure on the developing brain can occur through inhibition of axonal growth. The toxic 
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effects of NH4+ exposure on neurofilament protein expression and phosphorylation, on axonal 
growth, on signaling pathways and on the creatine content of brain cells are illustrated in red. 
Neuroprotection strategies to counteract NH4+ neurotoxicity are illustrated in green. A: 
Normal conditions of brain development. B: Hyperammonemia during brain development. 
MAPKs: mitogen activated protein kinase pathways; NFs: neurofilament proteins; P-NFs: 
phosphorylated neurofilaments. 
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